Role of 5 alpha-reductase inhibitors in the management of prostate cancer. - Wikidata - wikimedia - TriplyDB

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

http://www.wikidata.org/entity/Q37018960

about

Reliable and sensitive determination of dutasteride in human plasma by liquid chromatography-tandem mass spectrometry.The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?Drugs for benign prostatic hypertrophy

P2860

Q34699466-5476F220-68C0-405E-A564-B95297EA6D33 Q37526440-70E0C8DC-9C81-4723-8517-8FC60571F461 Q58588902-51CA4B7C-9FF3-4CB4-AA2E-29F77127D8D8

P2860

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

http://www.wikidata.org/entity/Q37018960

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2006

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@en

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@nl

type

label

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@en

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@nl

prefLabel

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@en

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@nl

P1433

Q37018960-FCAFF240-3674-465D-B060-37DCF14311AE

P1476

Q37018960-06044604-9565-44C4-A591-10083CDC9D0C

P2093

Q37018960-6A2102C4-3707-4CB2-92DF-6D5725D13EB1

Q37018960-951629D0-8A7F-4463-A5C5-E603E03C8A33

Q37018960-9D6211F9-9038-492B-BC0F-958820A006E0

P2860

Q37018960-07B11D31-B52D-4856-BD58-F839675C9D88

Q37018960-22977227-375E-45BB-B9BB-3DD3A781EAB7

Q37018960-32ADFBB0-F7D1-420D-AC70-7ADC6A21998B

Q37018960-479A13A4-8977-400C-B558-C663C07FAD36

Q37018960-638E8145-1F48-4FAE-AA89-B9D26C08424A

Q37018960-64DB688C-8A78-47DC-996C-CC019DA9845E

Q37018960-6647DBDC-9340-4286-B3B2-B11B9F8593D4

Q37018960-77619DA0-57FB-4A5D-A0C7-86D609544C48

Q37018960-7C5B0319-36FF-4FEB-A4AB-76E04D6679AD

Q37018960-81BDAFB8-4555-4F4E-A1CF-63D04988B4D4

P304

Q37018960-A663D484-21AC-472E-9D78-6EA167212436

P31

Q37018960-501ACD70-BBE7-472F-8B2F-D9438AFF3A12

Q37018960-E4A6C567-B8DA-4921-B34F-3699E4AE3957

P356

Q37018960-21046A60-1E75-477E-9EC5-3FD93CCFD56A

P407

Q37018960-D44B883A-EAD5-4648-BAF6-245675E78BB0

P433

Q37018960-AA4A9024-BEA4-47EE-9890-10DB55D21400

P478

Q37018960-09974802-CF93-4BA9-979A-2B31145CB934

P577

Q37018960-DED85A1B-4AD9-4A58-AE16-D276B1B9E8D7

P5875

Q37018960-30735F0C-ACCC-4482-911E-E8A67FE763E6

P698

Q37018960-AC072A52-DB40-43E4-8E9F-8B918B5D053C

P921

Q37018960-1FA56487-C960-4BCE-93E6-F484FA5F8BFD

Q37018960-3D531F5F-CBF3-4EB6-BEB8-02E41498DA36

Q37018960-749B867A-C853-4135-827B-79025ADACDB2

Q37018960-FD6FD718-D50C-491B-AEA4-525A9808AF7F

P932

Q37018960-563BF92D-D07F-4CA8-BE93-55A51A8FE4F3

P356

CIIA.2006.1.4.425

P1433

Clinical Interventions in Aging

P1476

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

@en

P2093

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Javier Hernandez

http://www.w3.org/2001/XMLSchema#string

Steven J Hudak

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2006

A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.

The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.

P304

425-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CIIA.2006.1.4.425

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5800848

http://www.w3.org/2001/XMLSchema#string

P698

18046919

http://www.w3.org/2001/XMLSchema#string

P921

hormone antagonist

prostate cancer

mechanism of action

polycyclic compound

P932

2699636

http://www.w3.org/2001/XMLSchema#string